DCN and cancer: Moreover, the relevance of decorin in cancer progression has been demonstrated in mutant mice where ∼30% of decorin-null mice develop spontaneous intestinal tumors [50], whereas decorin-null mice carrying a targeted disruption in p53 succumb within 3–4 months to aggressive lymphomas [51].